Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas

Journal of Clinical Oncology

Volumn 27, Issue 11, 2009, Pages 1893-1898

  Maurel, Joan ^a   López Pousa, Antonio ^b   De Las Peñas, Ramón ^b   Fra, Joaquín ^b   Martín, Javier ^b   Cruz, Josefina ^b   Casado, Antonio ^b   Poveda, Andrós ^b   Martínez Trufero, Javier ^b   Balañá, Carmen ^b   Gómez, María Auxiliadora ^b   Cubedo, Ricardo ^b   Gallego, Oscar ^b   Rubio Viqueira, Belen ^b   Rubió, Jordi ^b   Andrós, Raquel ^b   Sevilla, Isabel ^b   De La Cruz, Juan Jose ^b   Del Muro, Xavier García ^b   Buesa, Jose María ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; SPAIN; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; REMISSION INDUCTION; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64749115863     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.2930     Document Type: Article

References (18)

1. van Glabekke M, van Oosterom AT, Oosterhuis JW, et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline- containing first-line regimens-A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17:150-157, 1999
2. Van Glabbeke M, Verwij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
3. Santoro A, Rouesse J, Steward W, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537-1545, 1995
4. Buesa JM, Lopez-Pousa A, Martin J, et al: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcoma of adult: A study of the Spanish Group for Research on Sarcomas. Ann Oncol 9:871-876, 1998
5. Lorigan P, Verweij J, Papai Z, et al: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 25:3144-3150, 2007
6. Frustaci S, Buonadonna A, Galligioni E, et al: Increasing 4-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony- stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 15:1418-1426, 1997
7. Reichardt P, Tilgner J, Hohenberger P, et al: Dose-intensive chemotherapy with ifosfamide, epirubucin, and filgastrin for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 16:1438-1443, 1998
8. Patel SR, Vadhan-Raj S, Burgess MA, et al: Results of two consecutives trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21:317-321,1998
9. De Pas T, De Braud F, Orlando L, et al: High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible? Ann Oncol 9:917-919, 1998
10. Bokemeyer C, Franzke A, Hartmann JT, et al: A phase I/II study of sequential, dose-escalated, high-dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 80:1221-1227, 1997
11. Leyvraz S, Bacchi M, Cerny T, et al: Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Ann Oncol 9:877-884, 1998
12. López-Pousa A, Martín J, Montalar J, et al: The Spanish Group for Research on Sarcomas Geis: Phase II trial of doxorubicin plus escalated high-dose ifosf- amide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 1-8, 2006
13. Maurel J, Fra J, Lopez-Pousa A, et al: Spanish Group for Research on Sarcomas (GEIS): Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: A phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 100:1498-1506, 2004
14. Maurel J, Buesa J, López-Pousa A, et al: Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias-a study of the Spanish Group for Research on Sarcomas (GEIS). J Surg Oncol 88:44-49, 2004
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Lopez M, Vici P, Di Lauro L, et al: Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 20:1329-1334, 2002
17. Nielsen OS, Dombernowsky P, Mouridsen H, et al: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcoma: A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78:1634-1639, 1998
18. Van Glabbeke M, Steward W, Armand JP: Non-randomized phase II trials of drug combinations: Often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer 38:635-638, 2002